January 2009 Br J Cardiol 2009;16(Suppl 1):S2-S3
Henry Purcell
Diagnosis can be challenging as its symptoms are often non-specific: they may include breathlessness, fatigue, weakness, angina, syncope and abdominal distension. In the mid-1980s, before the availability of ‘targeted’ therapy, median life expectancy from diagnosis in patients with idiopathic PAH (formerly termed primary pulmonary hypertension [PPH]) was only 2.8 years.3 In 1996, continuous intravenous prostacyclin (epoprostenol) was the first drug to demonstrate outcome benefit in PAH.4 Subsequently, over the past ten years, randomised, placebo-controlled trials of other prostacyclin analogues, endothelin receptor antagonists and phospho
July 2008 Br J Cardiol 2008;15:215-6
Didier Locca, Ciara Bucciarelli-Ducci, Sanjay K Prasad
Case report Figure 1. Electrocardiogram (ECG) features of left ventricular hypertrophy A 67-year-old man was referred to the cardiology clinic with a history of collapse and a family history of hypertrophic cardiomyopathy (HCM). He denied any history of angina or dyspnoea. On physical examination he had a 3/6 grade ejection murmur in the aortic area and a pansystolic murmur at the mitral area accentuated on squatting. There were no signs of volume overload. X-ray angiography demonstrated normal coronaries but a raised end diastolic pressure. His electrocardiogram (ECG) was compatible with left ventricular (LV) hypertrophy (figure 1). A single
November 2003 Br J Cardiol 2003;10:418-20
Neil R Poulter
No content available
November 2002 Br J Cardiol 2002;9:615-6
Michael Pitt, Stephen Rooney, R Gordon Murray
No content available
January 2002 Br J Cardiol 2002;9:50-2
Oliver R Segal, Kevin Fox
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits